INTRODUCTION: In recent years, several novel anticoagulants have been approved for the prevention of thromboembolic strokes as an alternative to warfarin in patients with atrial arrhythmias. Studies have evaluated these medications in patients undergoing radiofrequency ablation, yet no data exists to evaluate the bleeding risk in patients undergoing cryoballoon ablation procedures. METHODS: Patients that underwent either cryoballoon ablation alone or with additional radiofrequency ablation over the past 3 years were included in the study. Patients were stratified into one of three subsets based on type of anticoagulation (warfarin, dabigatran, or rivaroxaban). Bleeding complications during the first 48 h and first 2 weeks following the ablation were recorded. Major complications were defined as hemorrhage requiring blood products or need for vascular intervention. Minor complications included prolonged bleeding from catheter insertion site, development of ecchymosis, or hematoma formation. Intraprocedural activated clotting times (ACT) were assessed and compared. RESULTS: A total of 217 patients met inclusion criteria of which 87 (40.1 %) patients were on warfarin, 90 (41.5 %) patients on dabigatran, and 40 (18.4 %) patients on rivaroxaban. The overall bleeding complication rate was 12.0 %. All complications occurred within the first 48 h post-ablation. Nine (10.3 %) complications occurred in the warfarin subset, ten (11.1 %) in the rivaroxaban subset, and seven (17.5 %) in the dabigatran subset (p = 0.49). The warfarin and dabigatran subsets had higher average ACT levels (424.9 versus 406.5) compared to the rivaroxaban subset (393.4; p < 0.01). Subanalyses found no difference in bleeding complications based on procedure type. CONCLUSION: Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. Compared with radiofrequency ablation, cryoablation does not place patients at an increased bleeding risk.
INTRODUCTION: In recent years, several novel anticoagulants have been approved for the prevention of thromboembolic strokes as an alternative to warfarin in patients with atrial arrhythmias. Studies have evaluated these medications in patients undergoing radiofrequency ablation, yet no data exists to evaluate the bleeding risk in patients undergoing cryoballoon ablation procedures. METHODS:Patients that underwent either cryoballoon ablation alone or with additional radiofrequency ablation over the past 3 years were included in the study. Patients were stratified into one of three subsets based on type of anticoagulation (warfarin, dabigatran, or rivaroxaban). Bleeding complications during the first 48 h and first 2 weeks following the ablation were recorded. Major complications were defined as hemorrhage requiring blood products or need for vascular intervention. Minor complications included prolonged bleeding from catheter insertion site, development of ecchymosis, or hematoma formation. Intraprocedural activated clotting times (ACT) were assessed and compared. RESULTS: A total of 217 patients met inclusion criteria of which 87 (40.1 %) patients were on warfarin, 90 (41.5 %) patients on dabigatran, and 40 (18.4 %) patients on rivaroxaban. The overall bleeding complication rate was 12.0 %. All complications occurred within the first 48 h post-ablation. Nine (10.3 %) complications occurred in the warfarin subset, ten (11.1 %) in the rivaroxaban subset, and seven (17.5 %) in the dabigatran subset (p = 0.49). The warfarin and dabigatran subsets had higher average ACT levels (424.9 versus 406.5) compared to the rivaroxaban subset (393.4; p < 0.01). Subanalyses found no difference in bleeding complications based on procedure type. CONCLUSION:Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. Compared with radiofrequency ablation, cryoablation does not place patients at an increased bleeding risk.
Authors: Dhanunjaya Lakkireddy; Yeruva Madhu Reddy; Luigi Di Biase; Subba Reddy Vanga; Pasquale Santangeli; Vijay Swarup; Rhea Pimentel; Moussa C Mansour; Andre D'Avila; Javier E Sanchez; J David Burkhardt; Fadi Chalhoub; Prasant Mohanty; James Coffey; Naushad Shaik; George Monir; Vivek Y Reddy; Jeremy Ruskin; Andrea Natale Journal: J Am Coll Cardiol Date: 2012-02-01 Impact factor: 24.094
Authors: Muzahir H Tayebjee; Ross J Hunter; Victoria Baker; Antonio Creta; Edward Duncan; Simon Sporton; Mark J Earley; Richard J Schilling Journal: Europace Date: 2011-05-13 Impact factor: 5.214
Authors: Hung-Fat Tse; Sven Reek; Carl Timmermans; Kathy Lai-Fun Lee; J Christoph Geller; Luz-Maria Rodriguez; Benoit Ghaye; Gregory M Ayers; Harry J G M Crijns; Helmut U Klein; Chu-Pak Lau Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Charlotte Eitel; Julia Koch; Philipp Sommer; Silke John; Simon Kircher; Andreas Bollmann; Arash Arya; Christopher Piorkowski; Gerhard Hindricks Journal: Europace Date: 2013-05-22 Impact factor: 5.214
Authors: Douglas L Packer; Robert C Kowal; Kevin R Wheelan; James M Irwin; Jean Champagne; Peter G Guerra; Marc Dubuc; Vivek Reddy; Linda Nelson; Richard G Holcomb; John W Lehmann; Jeremy N Ruskin Journal: J Am Coll Cardiol Date: 2013-03-21 Impact factor: 24.094
Authors: L C Brendel; F Dobler; G Hessling; J Michel; S L Braun; A L Steinsiek; P Groha; R Eckl; I Deisenhofer; A Hyseni; M Roest; I Ott; B Steppich Journal: J Interv Card Electrophysiol Date: 2017-07-22 Impact factor: 1.900
Authors: Aref A Bin Abdulhak; Kevin F Kennedy; Sanjaya Gupta; Michael Giocondo; Brian Ramza; Alan P Wimmer Journal: J Interv Card Electrophysiol Date: 2015-08-21 Impact factor: 1.900
Authors: Verena Tscholl; Abdullah Khaled-A Lsharaf; Tina Lin; Barbara Bellmann; Patrick Nagel; Klaus Lenz; Ulf Landmesser; Mattias Roser; Andreas Rillig Journal: Clin Cardiol Date: 2017-08-28 Impact factor: 2.882
Authors: Mate Vamos; Riccardo Cappato; Francis E Marchlinski; Andrea Natale; Stefan H Hohnloser Journal: Europace Date: 2016-01-20 Impact factor: 5.214